Sara Cipriani

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease
    Sara Cipriani
    Neurology Department, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 7:e37331. 2012
  2. pmc Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis
    Sara Cipriani
    Massachusetts General Hospital, 114 16th Street, Boston, MA 02129, USA
    Biomark Med 4:701-12. 2010
  3. pmc Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration
    Xiqun Chen
    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA
    Proc Natl Acad Sci U S A 110:300-5. 2013
  4. pmc Protection of dopaminergic cells by urate requires its accumulation in astrocytes
    Sara Cipriani
    Molecular Neurobiology Laboratory, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA 02129, USA
    J Neurochem 123:172-81. 2012

Detail Information

Publications4

  1. pmc Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease
    Sara Cipriani
    Neurology Department, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 7:e37331. 2012
    ..Our findings correlate intracellular urate content in dopaminergic neurons with their toxin resistance in a cellular model of PD and suggest a facilitative role for astrocytes in the neuroprotective effect of urate...
  2. pmc Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis
    Sara Cipriani
    Massachusetts General Hospital, 114 16th Street, Boston, MA 02129, USA
    Biomark Med 4:701-12. 2010
    ..In this article we review the convergent biological, epidemiological and clinical data that identify urate as a promising biomarker of the risk, diagnosis and prognosis of PD...
  3. pmc Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration
    Xiqun Chen
    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA
    Proc Natl Acad Sci U S A 110:300-5. 2013
    ..Together our data support a neuroprotective role of endogenous urate in dopaminergic neurons and strengthen the rationale for developing urate-elevating strategies as potential disease-modifying therapy for PD...
  4. pmc Protection of dopaminergic cells by urate requires its accumulation in astrocytes
    Sara Cipriani
    Molecular Neurobiology Laboratory, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA 02129, USA
    J Neurochem 123:172-81. 2012
    ..These data indicate that urate might act within astrocytes to trigger release of molecule(s) that are protective for dopaminergic cells...